SRS15958425 SAMN32028203 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line K7 cell_subtype EBS-protocol cell_type differentiating induced macrophages dev_stage day -4 of differentiating treatment The generation of iMacs using the EBS protocol (EBS-iMacs) was performed as described earlier [Nenasheva et al., 2020]. Briefly, iPSCs were expanded on MEFs, collected using collagenase IV in a way to preserve colony integrity, placed in ultralow adhesive 6-well plates and cultured in supplemented KO-DMEM medium (15% KOSR, 2µM Glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) to allow EB formation (day -4). Four days later (day 0), the generated EBs were harvested, transferred to tissue-culture 6-well plates (15-20 EBs/well) and cultured in supplemented X-VIVO 15 medium (2µM Glutamax, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) with the addition of IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Full medium change was performed every 7 days. When floating monocytic precursors of iMacs appeared in the cultures, they were collected, transferred to new wells and cultured in supplemented RPMI-1640 medium (10% FCS, 2 µM L-Glutamax, 1% non-essential amino acids, 1 % penicillin/streptomycin, 0.055 mM β-mercaptoethanol) containing M-CSF (50 ng/ml) to induce terminal differentiation of EBS-iMacs. The remaining cultures were restimulated with supplemented X-VIVO 15 medium containing IL3/M-CSF for another round of iMac generation. BioSampleModel Human SRS15958426 SAMN32028204 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line K7 cell_subtype EBS-protocol cell_type differentiating induced macrophages dev_stage day 0 of differentiating treatment The generation of iMacs using the EBS protocol (EBS-iMacs) was performed as described earlier [Nenasheva et al., 2020]. Briefly, iPSCs were expanded on MEFs, collected using collagenase IV in a way to preserve colony integrity, placed in ultralow adhesive 6-well plates and cultured in supplemented KO-DMEM medium (15% KOSR, 2µM Glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) to allow EB formation (day -4). Four days later (day 0), the generated EBs were harvested, transferred to tissue-culture 6-well plates (15-20 EBs/well) and cultured in supplemented X-VIVO 15 medium (2µM Glutamax, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) with the addition of IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Full medium change was performed every 7 days. When floating monocytic precursors of iMacs appeared in the cultures, they were collected, transferred to new wells and cultured in supplemented RPMI-1640 medium (10% FCS, 2 µM L-Glutamax, 1% non-essential amino acids, 1 % penicillin/streptomycin, 0.055 mM β-mercaptoethanol) containing M-CSF (50 ng/ml) to induce terminal differentiation of EBS-iMacs. The remaining cultures were restimulated with supplemented X-VIVO 15 medium containing IL3/M-CSF for another round of iMac generation. BioSampleModel Human SRS15958427 SAMN32028213 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line iMA cell_subtype EBS-protocol cell_type differentiating induced macrophages dev_stage day -4 of differentiating treatment The generation of iMacs using the EBS protocol (EBS-iMacs) was performed as described earlier [Nenasheva et al., 2020]. Briefly, iPSCs were expanded on MEFs, collected using collagenase IV in a way to preserve colony integrity, placed in ultralow adhesive 6-well plates and cultured in supplemented KO-DMEM medium (15% KOSR, 2µM Glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) to allow EB formation (day -4). Four days later (day 0), the generated EBs were harvested, transferred to tissue-culture 6-well plates (15-20 EBs/well) and cultured in supplemented X-VIVO 15 medium (2µM Glutamax, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) with the addition of IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Full medium change was performed every 7 days. When floating monocytic precursors of iMacs appeared in the cultures, they were collected, transferred to new wells and cultured in supplemented RPMI-1640 medium (10% FCS, 2 µM L-Glutamax, 1% non-essential amino acids, 1 % penicillin/streptomycin, 0.055 mM β-mercaptoethanol) containing M-CSF (50 ng/ml) to induce terminal differentiation of EBS-iMacs. The remaining cultures were restimulated with supplemented X-VIVO 15 medium containing IL3/M-CSF for another round of iMac generation. BioSampleModel Human SRS15958428 SAMN32028214 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line iMA cell_subtype EBS-protocol cell_type differentiating induced macrophages dev_stage day 0 of differentiating treatment The generation of iMacs using the EBS protocol (EBS-iMacs) was performed as described earlier [Nenasheva et al., 2020]. Briefly, iPSCs were expanded on MEFs, collected using collagenase IV in a way to preserve colony integrity, placed in ultralow adhesive 6-well plates and cultured in supplemented KO-DMEM medium (15% KOSR, 2µM Glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) to allow EB formation (day -4). Four days later (day 0), the generated EBs were harvested, transferred to tissue-culture 6-well plates (15-20 EBs/well) and cultured in supplemented X-VIVO 15 medium (2µM Glutamax, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) with the addition of IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Full medium change was performed every 7 days. When floating monocytic precursors of iMacs appeared in the cultures, they were collected, transferred to new wells and cultured in supplemented RPMI-1640 medium (10% FCS, 2 µM L-Glutamax, 1% non-essential amino acids, 1 % penicillin/streptomycin, 0.055 mM β-mercaptoethanol) containing M-CSF (50 ng/ml) to induce terminal differentiation of EBS-iMacs. The remaining cultures were restimulated with supplemented X-VIVO 15 medium containing IL3/M-CSF for another round of iMac generation. BioSampleModel Human SRS15958429 SAMN32028215 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line iMA cell_subtype EBS-protocol cell_type differentiating induced macrophages dev_stage day 6 of differentiating treatment The generation of iMacs using the EBS protocol (EBS-iMacs) was performed as described earlier [Nenasheva et al., 2020]. Briefly, iPSCs were expanded on MEFs, collected using collagenase IV in a way to preserve colony integrity, placed in ultralow adhesive 6-well plates and cultured in supplemented KO-DMEM medium (15% KOSR, 2µM Glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) to allow EB formation (day -4). Four days later (day 0), the generated EBs were harvested, transferred to tissue-culture 6-well plates (15-20 EBs/well) and cultured in supplemented X-VIVO 15 medium (2µM Glutamax, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) with the addition of IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Full medium change was performed every 7 days. When floating monocytic precursors of iMacs appeared in the cultures, they were collected, transferred to new wells and cultured in supplemented RPMI-1640 medium (10% FCS, 2 µM L-Glutamax, 1% non-essential amino acids, 1 % penicillin/streptomycin, 0.055 mM β-mercaptoethanol) containing M-CSF (50 ng/ml) to induce terminal differentiation of EBS-iMacs. The remaining cultures were restimulated with supplemented X-VIVO 15 medium containing IL3/M-CSF for another round of iMac generation. BioSampleModel Human SRS15958430 SAMN32028216 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line iMA cell_subtype EBS-protocol cell_type differentiating induced macrophages dev_stage day 10 of differentiating treatment The generation of iMacs using the EBS protocol (EBS-iMacs) was performed as described earlier [Nenasheva et al., 2020]. Briefly, iPSCs were expanded on MEFs, collected using collagenase IV in a way to preserve colony integrity, placed in ultralow adhesive 6-well plates and cultured in supplemented KO-DMEM medium (15% KOSR, 2µM Glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) to allow EB formation (day -4). Four days later (day 0), the generated EBs were harvested, transferred to tissue-culture 6-well plates (15-20 EBs/well) and cultured in supplemented X-VIVO 15 medium (2µM Glutamax, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) with the addition of IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Full medium change was performed every 7 days. When floating monocytic precursors of iMacs appeared in the cultures, they were collected, transferred to new wells and cultured in supplemented RPMI-1640 medium (10% FCS, 2 µM L-Glutamax, 1% non-essential amino acids, 1 % penicillin/streptomycin, 0.055 mM β-mercaptoethanol) containing M-CSF (50 ng/ml) to induce terminal differentiation of EBS-iMacs. The remaining cultures were restimulated with supplemented X-VIVO 15 medium containing IL3/M-CSF for another round of iMac generation. BioSampleModel Human SRS15958431 SAMN32028218 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line iMA cell_subtype 2DF-protocol cell_type differentiating induced macrophages dev_stage day -4 of differentiating treatment The generation of iMacs using the 2DF protocol (2DF-iMacs) was performed as it was previously described by [Takata et al., 2017], with some modifications. Briefly, iPSCs were expanded on MEFs and depleted from MEFs by culturing them on Matrigel-coated tissue culture plates in mTeSRTM1 medium for 2-3 days. MEF-depleted iPSC colonies were collected using collagenase IV and transferred to new Matrigel-treated tissue culture 6-well plates at 1:10-1:12 ratio (day -6). The cells were then cultured in StemPro-34 medium that was supplemented with mixtures of factors stimulating mesoderm/hemogenic endothelium (day -6 to day 0) and hematopoietic/myeloid differentiation (day 0 to day +10). The medium was changed every other day. On day +10, StemProTM-34 was replaced by supplemented RPMI-1640 medium containing M-CSF (50 ng/ml). The medium was changed every 3 days. When the first 2DF-iMacs appeared in the cultures (which usually occurred around day +19), they were collected and used for phenotypic and functional analysis or RNA isolation.The remaining cultures were re-stimulated with supplemented X-VIVO 15 medium containing IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Seven days later, monocyte-like precursors of 2DF-iMacs appeared in the cultures; they were collected, transferred to new 12-well or 6-well plates and cultured in supplemented RPMI-1640 medium containing M-CSF (50 ng/ml) for 7 days to obtain a new portion of 2DF-iMacs. The rounds of iMac generation were repeated multiple times while cell generation lasted (usually for more than 90 days). Culture conditions were hypoxic from day -6 to day +2 and normoxic starting day +2. BioSampleModel Human SRS15958432 SAMN32028217 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line iMA cell_subtype EBS-protocol cell_type differentiating induced macrophages dev_stage day 19 of differentiating treatment The generation of iMacs using the EBS protocol (EBS-iMacs) was performed as described earlier [Nenasheva et al., 2020]. Briefly, iPSCs were expanded on MEFs, collected using collagenase IV in a way to preserve colony integrity, placed in ultralow adhesive 6-well plates and cultured in supplemented KO-DMEM medium (15% KOSR, 2µM Glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) to allow EB formation (day -4). Four days later (day 0), the generated EBs were harvested, transferred to tissue-culture 6-well plates (15-20 EBs/well) and cultured in supplemented X-VIVO 15 medium (2µM Glutamax, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) with the addition of IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Full medium change was performed every 7 days. When floating monocytic precursors of iMacs appeared in the cultures, they were collected, transferred to new wells and cultured in supplemented RPMI-1640 medium (10% FCS, 2 µM L-Glutamax, 1% non-essential amino acids, 1 % penicillin/streptomycin, 0.055 mM β-mercaptoethanol) containing M-CSF (50 ng/ml) to induce terminal differentiation of EBS-iMacs. The remaining cultures were restimulated with supplemented X-VIVO 15 medium containing IL3/M-CSF for another round of iMac generation. BioSampleModel Human SRS15958433 SAMN32028219 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line iMA cell_subtype 2DF-protocol cell_type differentiating induced macrophages dev_stage day 0 of differentiating treatment The generation of iMacs using the 2DF protocol (2DF-iMacs) was performed as it was previously described by [Takata et al., 2017], with some modifications. Briefly, iPSCs were expanded on MEFs and depleted from MEFs by culturing them on Matrigel-coated tissue culture plates in mTeSRTM1 medium for 2-3 days. MEF-depleted iPSC colonies were collected using collagenase IV and transferred to new Matrigel-treated tissue culture 6-well plates at 1:10-1:12 ratio (day -6). The cells were then cultured in StemPro-34 medium that was supplemented with mixtures of factors stimulating mesoderm/hemogenic endothelium (day -6 to day 0) and hematopoietic/myeloid differentiation (day 0 to day +10). The medium was changed every other day. On day +10, StemProTM-34 was replaced by supplemented RPMI-1640 medium containing M-CSF (50 ng/ml). The medium was changed every 3 days. When the first 2DF-iMacs appeared in the cultures (which usually occurred around day +19), they were collected and used for phenotypic and functional analysis or RNA isolation.The remaining cultures were re-stimulated with supplemented X-VIVO 15 medium containing IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Seven days later, monocyte-like precursors of 2DF-iMacs appeared in the cultures; they were collected, transferred to new 12-well or 6-well plates and cultured in supplemented RPMI-1640 medium containing M-CSF (50 ng/ml) for 7 days to obtain a new portion of 2DF-iMacs. The rounds of iMac generation were repeated multiple times while cell generation lasted (usually for more than 90 days). Culture conditions were hypoxic from day -6 to day +2 and normoxic starting day +2. BioSampleModel Human SRS15958434 SAMN32028221 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line iMA cell_subtype 2DF-protocol cell_type differentiating induced macrophages dev_stage day 10 of differentiating treatment The generation of iMacs using the 2DF protocol (2DF-iMacs) was performed as it was previously described by [Takata et al., 2017], with some modifications. Briefly, iPSCs were expanded on MEFs and depleted from MEFs by culturing them on Matrigel-coated tissue culture plates in mTeSRTM1 medium for 2-3 days. MEF-depleted iPSC colonies were collected using collagenase IV and transferred to new Matrigel-treated tissue culture 6-well plates at 1:10-1:12 ratio (day -6). The cells were then cultured in StemPro-34 medium that was supplemented with mixtures of factors stimulating mesoderm/hemogenic endothelium (day -6 to day 0) and hematopoietic/myeloid differentiation (day 0 to day +10). The medium was changed every other day. On day +10, StemProTM-34 was replaced by supplemented RPMI-1640 medium containing M-CSF (50 ng/ml). The medium was changed every 3 days. When the first 2DF-iMacs appeared in the cultures (which usually occurred around day +19), they were collected and used for phenotypic and functional analysis or RNA isolation.The remaining cultures were re-stimulated with supplemented X-VIVO 15 medium containing IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Seven days later, monocyte-like precursors of 2DF-iMacs appeared in the cultures; they were collected, transferred to new 12-well or 6-well plates and cultured in supplemented RPMI-1640 medium containing M-CSF (50 ng/ml) for 7 days to obtain a new portion of 2DF-iMacs. The rounds of iMac generation were repeated multiple times while cell generation lasted (usually for more than 90 days). Culture conditions were hypoxic from day -6 to day +2 and normoxic starting day +2. BioSampleModel Human SRS15958435 SAMN32028220 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line iMA cell_subtype 2DF-protocol cell_type differentiating induced macrophages dev_stage day 6 of differentiating treatment The generation of iMacs using the 2DF protocol (2DF-iMacs) was performed as it was previously described by [Takata et al., 2017], with some modifications. Briefly, iPSCs were expanded on MEFs and depleted from MEFs by culturing them on Matrigel-coated tissue culture plates in mTeSRTM1 medium for 2-3 days. MEF-depleted iPSC colonies were collected using collagenase IV and transferred to new Matrigel-treated tissue culture 6-well plates at 1:10-1:12 ratio (day -6). The cells were then cultured in StemPro-34 medium that was supplemented with mixtures of factors stimulating mesoderm/hemogenic endothelium (day -6 to day 0) and hematopoietic/myeloid differentiation (day 0 to day +10). The medium was changed every other day. On day +10, StemProTM-34 was replaced by supplemented RPMI-1640 medium containing M-CSF (50 ng/ml). The medium was changed every 3 days. When the first 2DF-iMacs appeared in the cultures (which usually occurred around day +19), they were collected and used for phenotypic and functional analysis or RNA isolation.The remaining cultures were re-stimulated with supplemented X-VIVO 15 medium containing IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Seven days later, monocyte-like precursors of 2DF-iMacs appeared in the cultures; they were collected, transferred to new 12-well or 6-well plates and cultured in supplemented RPMI-1640 medium containing M-CSF (50 ng/ml) for 7 days to obtain a new portion of 2DF-iMacs. The rounds of iMac generation were repeated multiple times while cell generation lasted (usually for more than 90 days). Culture conditions were hypoxic from day -6 to day +2 and normoxic starting day +2. BioSampleModel Human SRS15958436 SAMN32028222 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line iMA cell_subtype 2DF-protocol cell_type differentiating induced macrophages dev_stage day 19 of differentiating treatment The generation of iMacs using the 2DF protocol (2DF-iMacs) was performed as it was previously described by [Takata et al., 2017], with some modifications. Briefly, iPSCs were expanded on MEFs and depleted from MEFs by culturing them on Matrigel-coated tissue culture plates in mTeSRTM1 medium for 2-3 days. MEF-depleted iPSC colonies were collected using collagenase IV and transferred to new Matrigel-treated tissue culture 6-well plates at 1:10-1:12 ratio (day -6). The cells were then cultured in StemPro-34 medium that was supplemented with mixtures of factors stimulating mesoderm/hemogenic endothelium (day -6 to day 0) and hematopoietic/myeloid differentiation (day 0 to day +10). The medium was changed every other day. On day +10, StemProTM-34 was replaced by supplemented RPMI-1640 medium containing M-CSF (50 ng/ml). The medium was changed every 3 days. When the first 2DF-iMacs appeared in the cultures (which usually occurred around day +19), they were collected and used for phenotypic and functional analysis or RNA isolation.The remaining cultures were re-stimulated with supplemented X-VIVO 15 medium containing IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Seven days later, monocyte-like precursors of 2DF-iMacs appeared in the cultures; they were collected, transferred to new 12-well or 6-well plates and cultured in supplemented RPMI-1640 medium containing M-CSF (50 ng/ml) for 7 days to obtain a new portion of 2DF-iMacs. The rounds of iMac generation were repeated multiple times while cell generation lasted (usually for more than 90 days). Culture conditions were hypoxic from day -6 to day +2 and normoxic starting day +2. BioSampleModel Human SRS15958437 SAMN32028205 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line K7 cell_subtype EBS-protocol cell_type differentiating induced macrophages dev_stage day 6 of differentiating treatment The generation of iMacs using the EBS protocol (EBS-iMacs) was performed as described earlier [Nenasheva et al., 2020]. Briefly, iPSCs were expanded on MEFs, collected using collagenase IV in a way to preserve colony integrity, placed in ultralow adhesive 6-well plates and cultured in supplemented KO-DMEM medium (15% KOSR, 2µM Glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) to allow EB formation (day -4). Four days later (day 0), the generated EBs were harvested, transferred to tissue-culture 6-well plates (15-20 EBs/well) and cultured in supplemented X-VIVO 15 medium (2µM Glutamax, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) with the addition of IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Full medium change was performed every 7 days. When floating monocytic precursors of iMacs appeared in the cultures, they were collected, transferred to new wells and cultured in supplemented RPMI-1640 medium (10% FCS, 2 µM L-Glutamax, 1% non-essential amino acids, 1 % penicillin/streptomycin, 0.055 mM β-mercaptoethanol) containing M-CSF (50 ng/ml) to induce terminal differentiation of EBS-iMacs. The remaining cultures were restimulated with supplemented X-VIVO 15 medium containing IL3/M-CSF for another round of iMac generation. BioSampleModel Human SRS15958438 SAMN32028226 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line K7 cell_subtype 2DF-protocol cell_type CD14+ FACS-sorted induced macrophages dev_stage differentiated iMacs treatment The generation of iMacs using the 2DF protocol (2DF-iMacs) was performed as it was previously described by [Takata et al., 2017], with some modifications. Briefly, iPSCs were expanded on MEFs and depleted from MEFs by culturing them on Matrigel-coated tissue culture plates in mTeSRTM1 medium for 2-3 days. MEF-depleted iPSC colonies were collected using collagenase IV and transferred to new Matrigel-treated tissue culture 6-well plates at 1:10-1:12 ratio (day -6). The cells were then cultured in StemPro-34 medium that was supplemented with mixtures of factors stimulating mesoderm/hemogenic endothelium (day -6 to day 0) and hematopoietic/myeloid differentiation (day 0 to day +10). The medium was changed every other day. On day +10, StemProTM-34 was replaced by supplemented RPMI-1640 medium containing M-CSF (50 ng/ml). The medium was changed every 3 days. When the first 2DF-iMacs appeared in the cultures (which usually occurred around day +19), they were collected and used for phenotypic and functional analysis or RNA isolation.The remaining cultures were re-stimulated with supplemented X-VIVO 15 medium containing IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Seven days later, monocyte-like precursors of 2DF-iMacs appeared in the cultures; they were collected, transferred to new 12-well or 6-well plates and cultured in supplemented RPMI-1640 medium containing M-CSF (50 ng/ml) for 7 days to obtain a new portion of 2DF-iMacs. The rounds of iMac generation were repeated multiple times while cell generation lasted (usually for more than 90 days). Culture conditions were hypoxic from day -6 to day +2 and normoxic starting day +2. BioSampleModel Human SRS15958439 SAMN32028225 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line K7 cell_subtype EBS-protocol cell_type CD14+ FACS-sorted induced macrophages dev_stage differentiated iMacs treatment The generation of iMacs using the EBS protocol (EBS-iMacs) was performed as described earlier [Nenasheva et al., 2020]. Briefly, iPSCs were expanded on MEFs, collected using collagenase IV in a way to preserve colony integrity, placed in ultralow adhesive 6-well plates and cultured in supplemented KO-DMEM medium (15% KOSR, 2µM Glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) to allow EB formation (day -4). Four days later (day 0), the generated EBs were harvested, transferred to tissue-culture 6-well plates (15-20 EBs/well) and cultured in supplemented X-VIVO 15 medium (2µM Glutamax, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) with the addition of IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Full medium change was performed every 7 days. When floating monocytic precursors of iMacs appeared in the cultures, they were collected, transferred to new wells and cultured in supplemented RPMI-1640 medium (10% FCS, 2 µM L-Glutamax, 1% non-essential amino acids, 1 % penicillin/streptomycin, 0.055 mM β-mercaptoethanol) containing M-CSF (50 ng/ml) to induce terminal differentiation of EBS-iMacs. The remaining cultures were restimulated with supplemented X-VIVO 15 medium containing IL3/M-CSF for another round of iMac generation. BioSampleModel Human SRS15958440 SAMN32028207 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line K7 cell_subtype EBS-protocol cell_type differentiating induced macrophages dev_stage day 19 of differentiating treatment The generation of iMacs using the EBS protocol (EBS-iMacs) was performed as described earlier [Nenasheva et al., 2020]. Briefly, iPSCs were expanded on MEFs, collected using collagenase IV in a way to preserve colony integrity, placed in ultralow adhesive 6-well plates and cultured in supplemented KO-DMEM medium (15% KOSR, 2µM Glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) to allow EB formation (day -4). Four days later (day 0), the generated EBs were harvested, transferred to tissue-culture 6-well plates (15-20 EBs/well) and cultured in supplemented X-VIVO 15 medium (2µM Glutamax, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) with the addition of IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Full medium change was performed every 7 days. When floating monocytic precursors of iMacs appeared in the cultures, they were collected, transferred to new wells and cultured in supplemented RPMI-1640 medium (10% FCS, 2 µM L-Glutamax, 1% non-essential amino acids, 1 % penicillin/streptomycin, 0.055 mM β-mercaptoethanol) containing M-CSF (50 ng/ml) to induce terminal differentiation of EBS-iMacs. The remaining cultures were restimulated with supplemented X-VIVO 15 medium containing IL3/M-CSF for another round of iMac generation. BioSampleModel Human SRS15958441 SAMN32028209 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line K7 cell_subtype 2DF-protocol cell_type differentiating induced macrophages dev_stage day 0 of differentiating treatment The generation of iMacs using the 2DF protocol (2DF-iMacs) was performed as it was previously described by [Takata et al., 2017], with some modifications. Briefly, iPSCs were expanded on MEFs and depleted from MEFs by culturing them on Matrigel-coated tissue culture plates in mTeSRTM1 medium for 2-3 days. MEF-depleted iPSC colonies were collected using collagenase IV and transferred to new Matrigel-treated tissue culture 6-well plates at 1:10-1:12 ratio (day -6). The cells were then cultured in StemPro-34 medium that was supplemented with mixtures of factors stimulating mesoderm/hemogenic endothelium (day -6 to day 0) and hematopoietic/myeloid differentiation (day 0 to day +10). The medium was changed every other day. On day +10, StemProTM-34 was replaced by supplemented RPMI-1640 medium containing M-CSF (50 ng/ml). The medium was changed every 3 days. When the first 2DF-iMacs appeared in the cultures (which usually occurred around day +19), they were collected and used for phenotypic and functional analysis or RNA isolation.The remaining cultures were re-stimulated with supplemented X-VIVO 15 medium containing IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Seven days later, monocyte-like precursors of 2DF-iMacs appeared in the cultures; they were collected, transferred to new 12-well or 6-well plates and cultured in supplemented RPMI-1640 medium containing M-CSF (50 ng/ml) for 7 days to obtain a new portion of 2DF-iMacs. The rounds of iMac generation were repeated multiple times while cell generation lasted (usually for more than 90 days). Culture conditions were hypoxic from day -6 to day +2 and normoxic starting day +2. BioSampleModel Human SRS15958442 SAMN32028208 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line K7 cell_subtype 2DF-protocol cell_type differentiating induced macrophages dev_stage day -4 of differentiating treatment The generation of iMacs using the 2DF protocol (2DF-iMacs) was performed as it was previously described by [Takata et al., 2017], with some modifications. Briefly, iPSCs were expanded on MEFs and depleted from MEFs by culturing them on Matrigel-coated tissue culture plates in mTeSRTM1 medium for 2-3 days. MEF-depleted iPSC colonies were collected using collagenase IV and transferred to new Matrigel-treated tissue culture 6-well plates at 1:10-1:12 ratio (day -6). The cells were then cultured in StemPro-34 medium that was supplemented with mixtures of factors stimulating mesoderm/hemogenic endothelium (day -6 to day 0) and hematopoietic/myeloid differentiation (day 0 to day +10). The medium was changed every other day. On day +10, StemProTM-34 was replaced by supplemented RPMI-1640 medium containing M-CSF (50 ng/ml). The medium was changed every 3 days. When the first 2DF-iMacs appeared in the cultures (which usually occurred around day +19), they were collected and used for phenotypic and functional analysis or RNA isolation.The remaining cultures were re-stimulated with supplemented X-VIVO 15 medium containing IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Seven days later, monocyte-like precursors of 2DF-iMacs appeared in the cultures; they were collected, transferred to new 12-well or 6-well plates and cultured in supplemented RPMI-1640 medium containing M-CSF (50 ng/ml) for 7 days to obtain a new portion of 2DF-iMacs. The rounds of iMac generation were repeated multiple times while cell generation lasted (usually for more than 90 days). Culture conditions were hypoxic from day -6 to day +2 and normoxic starting day +2. BioSampleModel Human SRS15958443 SAMN32028210 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line K7 cell_subtype 2DF-protocol cell_type differentiating induced macrophages dev_stage day 6 of differentiating treatment The generation of iMacs using the 2DF protocol (2DF-iMacs) was performed as it was previously described by [Takata et al., 2017], with some modifications. Briefly, iPSCs were expanded on MEFs and depleted from MEFs by culturing them on Matrigel-coated tissue culture plates in mTeSRTM1 medium for 2-3 days. MEF-depleted iPSC colonies were collected using collagenase IV and transferred to new Matrigel-treated tissue culture 6-well plates at 1:10-1:12 ratio (day -6). The cells were then cultured in StemPro-34 medium that was supplemented with mixtures of factors stimulating mesoderm/hemogenic endothelium (day -6 to day 0) and hematopoietic/myeloid differentiation (day 0 to day +10). The medium was changed every other day. On day +10, StemProTM-34 was replaced by supplemented RPMI-1640 medium containing M-CSF (50 ng/ml). The medium was changed every 3 days. When the first 2DF-iMacs appeared in the cultures (which usually occurred around day +19), they were collected and used for phenotypic and functional analysis or RNA isolation.The remaining cultures were re-stimulated with supplemented X-VIVO 15 medium containing IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Seven days later, monocyte-like precursors of 2DF-iMacs appeared in the cultures; they were collected, transferred to new 12-well or 6-well plates and cultured in supplemented RPMI-1640 medium containing M-CSF (50 ng/ml) for 7 days to obtain a new portion of 2DF-iMacs. The rounds of iMac generation were repeated multiple times while cell generation lasted (usually for more than 90 days). Culture conditions were hypoxic from day -6 to day +2 and normoxic starting day +2. BioSampleModel Human SRS15958444 SAMN32028212 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line K7 cell_subtype 2DF-protocol cell_type differentiating induced macrophages dev_stage day 19 of differentiating treatment The generation of iMacs using the 2DF protocol (2DF-iMacs) was performed as it was previously described by [Takata et al., 2017], with some modifications. Briefly, iPSCs were expanded on MEFs and depleted from MEFs by culturing them on Matrigel-coated tissue culture plates in mTeSRTM1 medium for 2-3 days. MEF-depleted iPSC colonies were collected using collagenase IV and transferred to new Matrigel-treated tissue culture 6-well plates at 1:10-1:12 ratio (day -6). The cells were then cultured in StemPro-34 medium that was supplemented with mixtures of factors stimulating mesoderm/hemogenic endothelium (day -6 to day 0) and hematopoietic/myeloid differentiation (day 0 to day +10). The medium was changed every other day. On day +10, StemProTM-34 was replaced by supplemented RPMI-1640 medium containing M-CSF (50 ng/ml). The medium was changed every 3 days. When the first 2DF-iMacs appeared in the cultures (which usually occurred around day +19), they were collected and used for phenotypic and functional analysis or RNA isolation.The remaining cultures were re-stimulated with supplemented X-VIVO 15 medium containing IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Seven days later, monocyte-like precursors of 2DF-iMacs appeared in the cultures; they were collected, transferred to new 12-well or 6-well plates and cultured in supplemented RPMI-1640 medium containing M-CSF (50 ng/ml) for 7 days to obtain a new portion of 2DF-iMacs. The rounds of iMac generation were repeated multiple times while cell generation lasted (usually for more than 90 days). Culture conditions were hypoxic from day -6 to day +2 and normoxic starting day +2. BioSampleModel Human SRS15958445 SAMN32028211 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line K7 cell_subtype 2DF-protocol cell_type differentiating induced macrophages dev_stage day 10 of differentiating treatment The generation of iMacs using the 2DF protocol (2DF-iMacs) was performed as it was previously described by [Takata et al., 2017], with some modifications. Briefly, iPSCs were expanded on MEFs and depleted from MEFs by culturing them on Matrigel-coated tissue culture plates in mTeSRTM1 medium for 2-3 days. MEF-depleted iPSC colonies were collected using collagenase IV and transferred to new Matrigel-treated tissue culture 6-well plates at 1:10-1:12 ratio (day -6). The cells were then cultured in StemPro-34 medium that was supplemented with mixtures of factors stimulating mesoderm/hemogenic endothelium (day -6 to day 0) and hematopoietic/myeloid differentiation (day 0 to day +10). The medium was changed every other day. On day +10, StemProTM-34 was replaced by supplemented RPMI-1640 medium containing M-CSF (50 ng/ml). The medium was changed every 3 days. When the first 2DF-iMacs appeared in the cultures (which usually occurred around day +19), they were collected and used for phenotypic and functional analysis or RNA isolation.The remaining cultures were re-stimulated with supplemented X-VIVO 15 medium containing IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Seven days later, monocyte-like precursors of 2DF-iMacs appeared in the cultures; they were collected, transferred to new 12-well or 6-well plates and cultured in supplemented RPMI-1640 medium containing M-CSF (50 ng/ml) for 7 days to obtain a new portion of 2DF-iMacs. The rounds of iMac generation were repeated multiple times while cell generation lasted (usually for more than 90 days). Culture conditions were hypoxic from day -6 to day +2 and normoxic starting day +2. BioSampleModel Human SRS15958446 SAMN32028224 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line iMA cell_subtype 2DF-protocol cell_type CD14+ FACS-sorted induced macrophages dev_stage differentiated iMacs treatment The generation of iMacs using the 2DF protocol (2DF-iMacs) was performed as it was previously described by [Takata et al., 2017], with some modifications. Briefly, iPSCs were expanded on MEFs and depleted from MEFs by culturing them on Matrigel-coated tissue culture plates in mTeSRTM1 medium for 2-3 days. MEF-depleted iPSC colonies were collected using collagenase IV and transferred to new Matrigel-treated tissue culture 6-well plates at 1:10-1:12 ratio (day -6). The cells were then cultured in StemPro-34 medium that was supplemented with mixtures of factors stimulating mesoderm/hemogenic endothelium (day -6 to day 0) and hematopoietic/myeloid differentiation (day 0 to day +10). The medium was changed every other day. On day +10, StemProTM-34 was replaced by supplemented RPMI-1640 medium containing M-CSF (50 ng/ml). The medium was changed every 3 days. When the first 2DF-iMacs appeared in the cultures (which usually occurred around day +19), they were collected and used for phenotypic and functional analysis or RNA isolation.The remaining cultures were re-stimulated with supplemented X-VIVO 15 medium containing IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Seven days later, monocyte-like precursors of 2DF-iMacs appeared in the cultures; they were collected, transferred to new 12-well or 6-well plates and cultured in supplemented RPMI-1640 medium containing M-CSF (50 ng/ml) for 7 days to obtain a new portion of 2DF-iMacs. The rounds of iMac generation were repeated multiple times while cell generation lasted (usually for more than 90 days). Culture conditions were hypoxic from day -6 to day +2 and normoxic starting day +2. BioSampleModel Human SRS15958447 SAMN32028206 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line K7 cell_subtype EBS-protocol cell_type differentiating induced macrophages dev_stage day 10 of differentiating treatment The generation of iMacs using the EBS protocol (EBS-iMacs) was performed as described earlier [Nenasheva et al., 2020]. Briefly, iPSCs were expanded on MEFs, collected using collagenase IV in a way to preserve colony integrity, placed in ultralow adhesive 6-well plates and cultured in supplemented KO-DMEM medium (15% KOSR, 2µM Glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) to allow EB formation (day -4). Four days later (day 0), the generated EBs were harvested, transferred to tissue-culture 6-well plates (15-20 EBs/well) and cultured in supplemented X-VIVO 15 medium (2µM Glutamax, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) with the addition of IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Full medium change was performed every 7 days. When floating monocytic precursors of iMacs appeared in the cultures, they were collected, transferred to new wells and cultured in supplemented RPMI-1640 medium (10% FCS, 2 µM L-Glutamax, 1% non-essential amino acids, 1 % penicillin/streptomycin, 0.055 mM β-mercaptoethanol) containing M-CSF (50 ng/ml) to induce terminal differentiation of EBS-iMacs. The remaining cultures were restimulated with supplemented X-VIVO 15 medium containing IL3/M-CSF for another round of iMac generation. BioSampleModel Human SRS15958448 SAMN32028223 9606 Homo sapiens bioproject 893554 isolate not applicable age not applicable biomaterial_provider IDB RAS sex not applicable tissue not applicable cell_line iMA cell_subtype EBS-protocol cell_type CD14+ FACS-sorted induced macrophages dev_stage differentiated iMacs treatment The generation of iMacs using the EBS protocol (EBS-iMacs) was performed as described earlier [Nenasheva et al., 2020]. Briefly, iPSCs were expanded on MEFs, collected using collagenase IV in a way to preserve colony integrity, placed in ultralow adhesive 6-well plates and cultured in supplemented KO-DMEM medium (15% KOSR, 2µM Glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) to allow EB formation (day -4). Four days later (day 0), the generated EBs were harvested, transferred to tissue-culture 6-well plates (15-20 EBs/well) and cultured in supplemented X-VIVO 15 medium (2µM Glutamax, 1% penicillin/streptomycin, 0,055mM β-mercaptoethanol) with the addition of IL-3 (25 ng/ml) and M-CSF (50 ng/ml). Full medium change was performed every 7 days. When floating monocytic precursors of iMacs appeared in the cultures, they were collected, transferred to new wells and cultured in supplemented RPMI-1640 medium (10% FCS, 2 µM L-Glutamax, 1% non-essential amino acids, 1 % penicillin/streptomycin, 0.055 mM β-mercaptoethanol) containing M-CSF (50 ng/ml) to induce terminal differentiation of EBS-iMacs. The remaining cultures were restimulated with supplemented X-VIVO 15 medium containing IL3/M-CSF for another round of iMac generation. BioSampleModel Human